NSE: AUROPHARMA · 22 October 2026
- Aurobindo Pharma Limited shares moved higher by 1.41% on Wednesday, trading near the upper end of the day's range between ₹1,548.00 and ₹1,605.00 after opening at ₹1,565.00.
- Aurobindo Pharma announced that it received final approval from the US Food & Drug Administration to manufacture and market Perampanel Tablets in strengths ranging from 2 mg to 12 mg. The product, bioequivalent to Catalyst Pharmaceuticals' Fycompa, will be manufactured at APL Healthcare's Unit-IV and is slated for launch in the third quarter of fiscal 2027, addressing an estimated market size of US$ 67 million.
- Trading volume was 1.23 times the 20-day average daily volume.
Why is Aurobindo Pharma share price rising on 22 October 2026?
Aurobindo Pharma Limited shares moved higher by 1.41% on Wednesday, trading near the upper end of the day's range between ₹1,548.00 and ₹1,605.00 after opening at ₹1,565.00.
The broader market exhibited weak sentiment as the Nifty benchmark declined 0.97%, while the Nifty Pharma sector index remained relatively flat with a minor loss of 0.07%. Aurobindo Pharma's positive price action stood out against the broader market pullback, reflecting stock-specific resilience following a multi-session corrective phase that included a 2.63% drop in the prior session and a 5.82% decline over the trailing 20 trading days.
Recent business updates from the company provide operational backdrop, including the U.S. launch of ADQUEY ointment through its subsidiary Acrotech Biopharma and the final USFDA approval for Perampanel Tablets. However, as these announcements occurred earlier in October 2026, today's positive price movement appears primarily aligned with a technical rebound following recent short-term weakness rather than a direct reaction to a same-day news catalyst.
10.71 lakh shares traded by 22 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 8.70 lakh shares (1.23 times). The five-day average daily volume was 8.83 lakh shares. Separately, the NSE report for 21 October 2026 showed 6.66 lakh shares delivered, representing 54.58% of that day’s traded volume. The same report recorded 83,318 trades.
The stock moved higher by 1.41% on above-average cash volume following a sustained multi-session pullback, with no same-day corporate announcements to directly attribute the session's gains to.
Latest Company Developments
Aurobindo Pharma announced that it received final approval from the US Food & Drug Administration to manufacture and market Perampanel Tablets in strengths ranging from 2 mg to 12 mg. The product, bioequivalent to Catalyst Pharmaceuticals' Fycompa, will be manufactured at APL Healthcare's Unit-IV and is slated for launch in the third quarter of fiscal 2027, addressing an estimated market size of US$ 67 million.
Expands the company's neurology portfolio in the regulated U.S. market with a targeted commercial rollout timeline.
The company completed the acquisition of the contract research services business of A1 Biochem Group through its subsidiary Apitoria Pharma. Following the transaction, Apitoria holds an 80% stake in A1 Biochem Labs India, while former promoter Dr. Rajendra Gadikota retains 20%, bringing U.S.-based chemistry and research capabilities into an integrated CRDMO platform.
Enhances Aurobindo's front-end research and development capabilities to offer full-service, longer life cycle engagement with pharmaceutical customers.
Acrotech Biopharma, a step-down subsidiary of Aurobindo Pharma, announced the U.S. launch of ADQUEY ointment for the treatment of mild-to-moderate atopic dermatitis in patients aged 2 years and older. Concurrently, Acrotech established a dedicated dermatology business unit to support healthcare professionals and expand its commercial footprint in specialized therapeutic segments.
Marks Acrotech's entry into the U.S. dermatology market, targeting a segment with an estimated market size of US$ 1.3 billion.
Aurobindo Pharma Limited has submitted the Exchange a copy Srutinizers report of AGM held on August 27, 2026. and voting results.
a press release dated October 03, 2026, titled "Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.31% on 30 September 2026. This compares with 16.71% on 30 June 2026, a change of -0.40 percentage points.
The filing reported 44 MF/UTI holders.
Research & Brokerage Views
Maintained a positive stance and updated price targets following strong operational performance and ongoing expansion in specialty and complex generic segments.
What to Watch Next
- Execution and market uptake of newly launched U.S. products including ADQUEY ointment and Perampanel tablets.
- Integration milestones and revenue contribution from the newly acquired A1 Biochem Group CRDMO platform.
- Sustained cash volume and delivery percentage trends relative to the 20-day average.
- Regulatory updates regarding upcoming USFDA facility inspections across manufacturing subsidiaries.
Other Dated Coverage
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 3.08% | 19 October 2026 — 19 October 2026
- Why Aurobindo Pharma Shares Slipped 0.11% Today Amid Sector Weakness | 5 October 2026 — 5 October 2026
- Aurobindo Pharma in Focus After U.S. ADQUEY Launch; What to Watch Today | 1 October 2026 — 1 October 2026
More Aurobindo Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Aurobindo Pharma company news?
Aurobindo Pharma announced that it received final approval from the US Food & Drug Administration to manufacture and market Perampanel Tablets in strengths ranging from 2 mg to 12 mg. The product, bioequivalent to Catalyst Pharmaceuticals' Fycompa, will be manufactured at APL Healthcare's Unit-IV and is slated for launch in the third quarter of fiscal 2027, addressing an estimated market size of US$ 67 million.
How strong was Aurobindo Pharma’s trading volume?
10.71 lakh shares traded, 1.23 times the 20-day average daily volume. The price and volume data are dated 22 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.